Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items (2016 - 2023)

Historic Non-cash Items for Editas Medicine (EDIT) over the last 9 years, with Q2 2023 value amounting to $466.2 million.

  • Editas Medicine's Non-cash Items rose 2536339.84% to $466.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $466.2 million, marking a year-over-year increase of 2536339.84%. This contributed to the annual value of $2.0 million for FY2022, which is 9995.97% down from last year.
  • Per Editas Medicine's latest filing, its Non-cash Items stood at $466.2 million for Q2 2023, which was up 2536339.84% from $236.5 million recorded in Q1 2023.
  • Over the past 5 years, Editas Medicine's Non-cash Items peaked at $5.1 billion during Q4 2021, and registered a low of $1.3 million during Q3 2021.
  • Moreover, its 5-year median value for Non-cash Items was $21.2 million (2019), whereas its average is $643.8 million.
  • Within the past 5 years, the most significant YoY rise in Editas Medicine's Non-cash Items was 26295133.43% (2022), while the steepest drop was 9995.97% (2022).
  • Over the past 5 years, Editas Medicine's Non-cash Items (Quarter) stood at $26.1 million in 2019, then soared by 543.28% to $167.6 million in 2020, then surged by 2913.88% to $5.1 billion in 2021, then crashed by 99.96% to $2.0 million in 2022, then soared by 22791.59% to $466.2 million in 2023.
  • Its Non-cash Items was $466.2 million in Q2 2023, compared to $236.5 million in Q1 2023 and $2.0 million in Q4 2022.